Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of 1,2,3,4,6-o-pentagalloylglucose in the preparation of medicaments for preventing and/or treating pulmonary fibrosis

A technology of pentagalloyl glucose and pulmonary fibrosis, which is applied in the field of medicine, can solve the problems that have not yet been treated, and achieve the effect of no toxic side effects and good resistance to pulmonary fibrosis

Active Publication Date: 2022-08-02
GUANGZHOU SHENGPU INVESTMENT MANAGEMENT
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] 1,2,3,4,6-O-Pentagalloyl Glucose (PGG) is the representative of natural ellagitannin, which belongs to the hydrolysis product of tannin, and naturally exists in various plants such as salt bran, peony, geranium, etc. It has various physiological activities such as inhibiting biological enzymes, antibacterial, antiviral, anti-inflammatory, anticancer, antidiabetic, antiplatelet, etc., but there is no research on its treatment of diseases related to pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 1,2,3,4,6-o-pentagalloylglucose in the preparation of medicaments for preventing and/or treating pulmonary fibrosis
  • Application of 1,2,3,4,6-o-pentagalloylglucose in the preparation of medicaments for preventing and/or treating pulmonary fibrosis
  • Application of 1,2,3,4,6-o-pentagalloylglucose in the preparation of medicaments for preventing and/or treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1 Inhibitory effect of 1,2,3,4,6-O-pentagalloglucose on the proliferation of lung fibroblasts

[0073] 1. Experimental method

[0074] Lung fibroblasts were purchased from Fenghui Biological Cell Company.

[0075] (1) Cell culture

[0076] Lung fibroblasts were cultured in high-glucose DMEM medium containing 10% fetal bovine serum, 1% penicillin and streptomycin double antibody, and glucose concentration 4.5g / L, and the cells were placed at 37°C containing 5% CO. 2 Incubator, change the cell culture medium every 2d. When the cell density is 80% to 90%, trypsinize and resuspend the cells for passage.

[0077] (2) Administration

[0078] After observing that the cells grow well, the cells were digested and resuspended, and the fibroblasts were seeded on a black 96-well plate at a density of 3000 cells per well. 24h after the cells were seeded, TGF-β at a concentration of 10ng / mL was added to each well 1 to establish a cellular pulmonary fibrosis model. Afte...

Embodiment 2

[0090] Example 2 1,2,3,4,6-O-pentagalloylglucose anti-pulmonary fibrosis test

[0091] 1. Experimental method

[0092] (1) SPF grade Wistar rats were randomly divided into 5 groups according to body weight, with 30 rats in each group. sham operation group, model group, 1,2,3,4,6-O-pentagalloylglucose high dose (500mg / (kg d)), medium dose (250mg / (kg d)) and low dose, respectively Dosage group (125 mg / (kg·d)).

[0093] (2) Model preparation

[0094] After the experimental animals were purchased, they were routinely raised and adapted to the environment for 7 days. During the experiment, the animals were anesthetized by intraperitoneal injection of 3 mL / kg of 10% trichloroacetaldehyde hydrate, and they were fixed on the mouse board in supine position, and their necks were sheared. The skin is routinely disinfected, and a mid-neck incision of about 0.5 to 1 cm in length is made under aseptic operation. Peel off the exposed trachea layer by layer, and then raise the head end o...

Embodiment 3

[0103] Example 3 1,2,3,4,6-O-pentagalloylglucose acute toxicity test

[0104] 1. Experimental method

[0105] Take the acute toxicity maximum tolerated dose method for the test. A blank group and a 1,2,3,4,6-O-pentagalloglucose (1.5g / mL) group were set up, a total of 2 groups, and 60 quarantine-qualified SPF ICR mice, half male and female, were selected. Gender and weight were randomly divided into two groups by segment, 30 animals in each group, fasted for more than 12 hours before administration, the blank group was not administered, and the drug group was given 0.4ml / 10g during the test. 体重 One-time intragastric administration. On the day of administration, especially within 0 to 4 hours after administration, closely observe and record the poisoning manifestations and characteristics of the animals in each group, the occurrence and recovery time of toxic reactions, and the death situation. Then observe twice a day, namely once in the morning and once in the afternoon, fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides the application of 1,2,3,4,6-O-pentagalloglucose (PGG) in the preparation of medicaments for preventing and / or treating pulmonary fibrosis. The present invention is the first to discover that PGG has a good therapeutic effect on pulmonary fibrosis without adverse reactions, which provides a new choice for the treatment of pulmonary fibrosis, and also provides a new natural drug for the treatment of pulmonary fibrosis. Source, efficient, safe, non-toxic and side effects.

Description

technical field [0001] The invention belongs to the technical field of medicine. More specifically, it relates to the use of 1,2,3,4,6-O-pentagalloglucose in the preparation of a medicament for preventing and / or treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis is the end-stage change of a large class of lung diseases characterized by the proliferation of fibroblasts and the accumulation of a large amount of extracellular matrix accompanied by inflammatory damage and tissue structure destruction. Abnormal (scarring). The vast majority of patients with pulmonary fibrosis are of unknown etiology (idiopathic). This group of diseases is called idiopathic interstitial pneumonia (IIP), which is a large category of interstitial lung diseases. The most common type of disease in idiopathic interstitial pneumonia (IIP) with pulmonary fibrosis as the main manifestation is idiopathic pulmonary fibrosis (IPF), which is a serious disease that can lead to prog...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/7034A61K9/08A61K9/20A61K9/48A61K9/12A61K47/10A61K47/22A61K47/36A61K47/38A61P11/00A23L33/125
CPCA61K31/7034A61K9/0095A61K47/10A61K9/2059A61K9/4866A61K9/12A61K9/0073A61K47/22A61P11/00A23L33/125A23V2002/00A23V2200/314
Inventor 付军
Owner GUANGZHOU SHENGPU INVESTMENT MANAGEMENT